Minitablets Coated in a Solid-Wall Pan for Theophylline Sustained-Release Capsules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Minitablets Coated in a Solid-Wall Pan for Theophylline Sustained-Release Capsules
The authors describe an alternative approach to compressing and coating minitablets for use in a sustained-release, solid oral-dosage form. This article is part of a special Drug Delivery issue.


Pharmaceutical Technology
pp. s38-s42

Results and discussion

The target of this study was to investigate from the industrial point of view the possibility of manufacturing a final solid-dosage form containing a multiparticulate system providing a controlled release of the drug. The work was divided into three steps: first the feasibility of producing minitablets by direct compression was evaluated, secondly the coating of the produced minitablets in a solid wall pan was studied, and finally the process of filling the minitablets into hard gelatine capsules was checked.

Four batches of minitablets containing an increased amount of TH from 50% to 80% (w/w) were produced and characterized in terms of weight variations, friability, and crushing strength. These four batches were labelled mT1, which contained 50% (w/w) TH; mT2, which contained 60% (w/w) TH; mT3, which contained 70% (w/w) TH; and mT4, which contained 80% (w/w) TH. Because the second step of the production was a film coating in a pan, particular attention had to be paid to friability and crushing strength to assess that the cores had enough mechanical resistance to tolerate the stress involved in pan coating, especially in production size.


Figure 4: Scanning electron microscopy images of the uncoated batch labeled "mT4" that was prepared by the authors. The images show formula A at different coating levels and formula B at different coating levels. (FIGURE COURTESY OF THE AUTHOR)
The results showed that all the formulations considered were successfully compressed into minitablets having small weight variations, high crushing strength, and very low friability (see Table IV). Among the produced batches, formulation mT4 was selected for the subsequent steps due to its high TH content, which enables the production of a 300-mg dosage unit.

The second part of the study was aimed at demonstrating the feasibility of coating minitablets in a solid-wall pan. The first challenge was to avoid coating defects. In fact all coating processes, if not properly controlled, could lead to defects such as sticking or twinning of two or more cores together, nonuniform distribution of the coating, peeling of the coating surface, weakness of the coating, especially cracking on the tablet edges, and coating roughness/orange-peel effect. For this reason, preliminary tests (not reported) were performed to find the best coating conditions. Different combinations of pan speed (range 15–24 rpm), atomization pressure (range 0.8–1.5 bar), inlet air temperature (range 55–65 C), inlet air quantity (range 200–250 m3/h); cores' temperature (range 30–35 C) and spray rate (range 30–45 ml/min.) were investigated to create process harmony.

The optimal combination of parameters found for the traditional coating formulation A are reported in Table II. Subsequently, the possibility of replacing the standard coating preparation with a ready-to-use system (formulation B) was tested with the aim to reduce both total process time (starting from the coating preparation) and the need for ancillary equipment.

Comparing Tables II and III, it is evident that for both formulation A and B the coating conditions were identical, which demonstrates the interchangeability of the traditional formula containing the single components with the ready-to-use pigment dispersion at least regarding the process parameters. Two different coating levels were tested for both coating formulas to check the influence of the amount of polymers on drug release.


Figure 5: Dissolution of uncoated and coated minitablets A and B at different total solid-weight gain. TH is theophylline, Awg is weight gain for formula A, and Bwg is weight gain for formula B. (FIGURE COURTESY OF THE AUTHOR)
To assess the coating quality, the surface characteristics and the cross-section slides of the coated minitablets were observed using scanning electron microscopy at different coating levels for either minitablets coated with the standard formula A and the innovative formula B (7). The results in Figure 4 show that a complete and uniform layer was achieved using both formulas even at low coating levels.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here